King's College London

Research portal

Biological variation of secretoneurin; a novel cardiovascular biomarker implicated in arrhythmogenesis

Research output: Contribution to journalArticlepeer-review

Kristin M. Aakre, Anett H. Ottesen, Heidi Strand, Arne L. Faaren, Bashir Alaour, Janniche Torsvik, Marit S. Sylte, Michael Marber, Geir Christensen, Helge Røsjø, Torbjørn Omland

Original languageEnglish
Pages (from-to)74-77
Number of pages4
JournalClinical Biochemistry
Early online date6 Oct 2021
Accepted/In press2021
E-pub ahead of print6 Oct 2021
PublishedDec 2021

Bibliographical note

Funding Information: The study was supported by a grant from the Dept. of Medical Biochemistry and Pharmacology, Haukeland University Hospital, a grant from the University of Oslo and grants from the Medical Research Council (London, UK) (G1000737), Guy's and St Thomas' Charity (London, UK; R060701, R100404), British Heart Foundation (Birmingham, London; TG/15/1/31518, FS/18/78/33902), and the UK Department of Health through the National Institute for Health Research Biomedical Research Centre award to Guy's & St Thomas' National Health Service Foundation Trust. Publisher Copyright: © 2021 The Author(s)

King's Authors


Background: Secretoneurin is a novel prognostic biomarker that may predict mortality in heart failure and the occurrence of ventricular arrhythmias. This study reports the within subject variation (CVI), between subject variation (CVG), reference change values (RCV) and index of individuality (II) of secretoneurin. Methods: Thirty healthy volunteers were included. Non-fasting samples were obtained between 8 and 10 am once a week for ten weeks. Secretoneurin was analyzed in duplicate using ELISA. No outliers were present according to Burnett and Reeds‘ criteria. Simple linear regression did not identify significant trends. Variance homogeneity in the analytical variance and CVI were tested using Cochrane's and Bartlett's tests and four participants were excluded. Calculation of CVI, CVG and RCV were done on ln transformed data as described by Fokkema, the II was calculated using retransformed data. Results: The median age of the participants was 36 years and 53% were female. Non-fasting glucose, eGFR(CKD-EPI), cTnT and NT-proBNP concentrations were within the normal range. Median secretoneurin concentrations were 38 pmol/L (women) and 33 pmol/L (men), p-value < 0.001. CVI and CVG were 9.8% (CI 8.7% to 11.0%) and 20.0 (CI 15.4% to 28.0%), respectively. RCV were 38.7% (CI 35.5% to 42.7%) and −27.9 (CI −29.9 to −26.2) and the II were 0.60 (CI 0.42–0.78). No gender differences were present. Conclusion: Secretoneurin has a fairly low CVI, CVG, RCV and II, indicating that it could be suitable as a diagnostic or prognostic biomarker and that delta values in serial samplings may be preferable for identifying clinical changes.

View graph of relations

© 2020 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454